Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies


You May Also Like

VBL Therapeutics Prices  2.5 Million Ordinary Share Offering

TEL AVIV, Israel, Nov. 17, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage ...

Mateon Provides Corporate Update and Reports Second Quarter 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), ...